Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Incyte’s pipeline updates on Monday bring into question the value of its $750 million Escient acquisition in April 2024—and ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

A PRODUCT from Aldi’s party food selection has been urgently recalled due to a possible allergy risk. Aldi customers who have ...